

# STK11 mutation affects tumor proliferation by impacting CD4<sup>+</sup> T cell activity in lung adenocarcinoma

JIEMENG GE, RUI FENG, FEIHU ZHU, ZHIHUI XU, QIANGWEI CHI, ZHENYE LV

Department of Cardiothoracic Surgery, Wenzhou People's Hospital, Wenzhou, China

## Abstract

**Introduction:** STK11 mutation is common in lung adenocarcinoma (LUAD), but the molecular mechanism of STK11 regulation in LUAD remains uncharacterized. This study intended to explore the effect of STK11 mutation on activity and proliferation of CD4<sup>+</sup> T cells in LUAD.

**Material and methods:** qRT-PCR experiments verified the STK11 level in different cell models. Cell Counting Kit-8 (CCK-8) and colony formation experiments evaluated proliferation ability. CCK-8 detected activity of CD4<sup>+</sup> T cells. Immunohistochemistry detected levels of related genes. Immunofluorescence assayed levels of CD4<sup>+</sup> T cell infiltration.

**Results:** STK11 mutation could accelerate proliferation of LUAD cells and impact activity of CD4<sup>+</sup> T cells. Further research found that STK11 mutation affected tumor proliferation by impacting CD4<sup>+</sup> T cell activity in LUAD.

**Conclusions:** This study revealed the regulatory mechanism of STK11 mutation affecting tumor proliferation by impacting CD4<sup>+</sup> T cell activity in LUAD. It suggested that STK11 may be a possible biological target for LUAD patients, and inhibiting STK11 mutation or cutting off its regulatory pathway for immune function may be an effective strategy for STK11-mutated tumor patients.

**Key words:** STK11 mutation, lung adenocarcinoma, CD4<sup>+</sup> T cells, proliferation, immunity.

(Cent Eur J Immunol 2024; 49 (3): 320-330)

## Introduction

Lung adenocarcinoma (LUAD) is a non-small cell lung cancer that originates from the inner wall cells of the lungs, representing 40% of all lung cancer cases [1-3]. Currently, therapeutic options for LUAD include surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy [4, 5]. Most targeted therapy drugs act on cancer-associated specific proteins, exerting various anti-cancer effects while causing relatively little damage to normal cells [6-9]. Similarly, the pharmacological mechanism of some drugs in immune therapy for LUAD is achieved by blocking the function of specific marker proteins, ultimately achieving therapeutic efficacy [10]. Targeted therapy and immune therapy targets are often proteins that are abnormally expressed or have abnormal structures in cancer cells, such as EGFR, ALK, ROS1, PD-L1, etc. [11]. STK11, as a classic biomarker, has a certain value for prognostic prediction of lung cancer patients [12].

One of the most frequently altered genes in LUAD is *STK11* [13]. The *STK11* gene produces a protein that functions as a tumor suppressor and is essential for regulating the development, proliferation, and differentiation of tumor cells [14, 15]. Therefore, in order to create more

potent targeted therapeutics, it is essential to comprehend the molecular basis of the STK11 mutation in LUAD. Similar to the common mutation of another gene, EGFR, in LUAD, EGFR inhibitors (such as gefitinib, erlotinib, and osimertinib) can block the function of the EGFR protein, and these drugs have shown good therapeutic effects in EGFR-mutated patients [16-18]. Serine/threonine kinase (BRAF) is another gene that can mutate and promote cancer growth in LUAD patients. BRAF inhibitors (such as dabrafenib and trametinib) can target the mutated BRAF protein and help slow tumor growth [19-21]. Despite the fact that there are no reports of STK11 inhibitors being used successfully right now, recent studies have shown that patients with STK11 mutation may benefit from targeted therapies, such as targeting the mTOR pathway [22] or Hippo pathway [23]. Therefore, exploring the regulatory pathways of STK11 has enormous potential for development in the treatment of LUAD.

CD4<sup>+</sup> T cells (helper T cells) are immune cells that are critical in adaptive immune responses [24, 25]. CD4<sup>+</sup> T cells regulate other cells in the immune system, and are essential for defending against intracellular pathogens (such as viruses and certain bacteria) and activating other

Correspondence: Zhenye Lv, Department of Cardiothoracic Surgery, Wenzhou People's Hospital, No. 299, Guan Road, Ouhai District, Wenzhou, 325006, China, phone: +86-13968888775, e-mail: lzy1852000@163.com  
Submitted: 22.03.2024, Accepted: 22.05.2024

immune cells (such as B cells and CD8<sup>+</sup> T cells) [26-28]. CD4<sup>+</sup> T cells have various subtypes, including Th1, Th2, Th17, Treg, and Tfh cells, each with unique functions and cytokine profiles [29, 30]. Th1 cells are involved in defense against intracellular pathogens [31], while Th2 cells play a role in the response to extracellular parasites, bacteria, allergens, and toxins [32-34]. Th17 cells are crucial for defense against bacteria and fungi [35], and Treg cells assist in controlling immune responses to prevent autoimmunity [36]. Defective CD4<sup>+</sup> T cell function can lead to immune deficiency diseases, such as HIV/AIDS [37, 38], while overactivation of CD4<sup>+</sup> T cells can lead to autoimmune diseases such as multiple sclerosis and lupus [39, 40]. CD4<sup>+</sup> T cells have a complex role in immune responses in cancer. First, CD4<sup>+</sup> T cells promote anti-tumor immune responses by activating other immune cells and helping to kill cancer cells [41, 42]. Second, CD4<sup>+</sup> T cells can actually drive cancer cell proliferation by providing growth factors and cytokines that stimulate cancer cell growth and division [43]. The current research focus is on finding a balance point between these pro-tumor and anti-tumor effects of CD4<sup>+</sup> T cells and developing new immunotherapies to enhance anti-tumor responses and facilitate prognosis of LUAD patients [44, 45]. The complex interactions between CD4<sup>+</sup> T cells and cancer cells in LUAD, and how best to target this relationship for therapeutic benefit, remain to be explored.

This study mainly investigated the impact of STK11 mutation in LUAD on the shape of LUAD cells and CD4<sup>+</sup> T cells by *in vitro* cell experiments. Finally, our study showed that STK11 mutation in LUAD cells could promote LUAD cell proliferation and migration while repressing the activity of CD4<sup>+</sup> T cells.

## Material and methods

### Clinical samples

Clinical information of patients who had not received any treatment was collected from Wenzhou People's Hospital between March 2022 and May 2023. By genetic detection, tumor tissues with wild-type STK11 ( $n = 15$ ) and tumor tissues with mutant-type STK11 ( $n = 15$ ) were found. All patients included in the study signed an informed consent form, and the experimental procedures involving clinical samples and information were approved by the Ethics Committee of Wenzhou People's Hospital.

**Table 1.** qRT-PCR primer sequences

Gene	Primer (5'-3')
STK11	F: TTTGAGAACATCGGGAAGGG
	R: CGGATGGAGAACCTCTTGG
$\beta$ -actin	F: CGTCACCAACTGGGACGACA
	R: CTTCTCGCGGTTGGCCTTGG

### Cell culture

A549, H460, and H2030 cells carrying STK11 mutation and the Calu-6 cells without STK11 mutation were accessed from ATCC (USA). The H460 and H2030 cells were cultured in RPMI-1640 complete medium with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (P-S), the A549 cells were cultured in F-12K complete medium with 10% FBS and 1% P-S, and Calu-6 cells were maintained in MEM complete medium with 10% FBS and 1% P-S. According to the *STK11* gene sequence, corresponding sgRNA sequences were designed and inserted into the eSpCas9-2A-GFP plasmid (GenScript, China). Lipofectamine 3000 (Thermo Fisher, USA) was utilized to transfect the plasmids into A549 and Calu-6 cells to construct A549<sup>STK11 RES</sup> and Calu6<sup>STK11 KD</sup> cell models, which were respectively cultured in F-12K and MEM complete medium with 10% FBS and 1% P-S at 37°C and 5% CO<sub>2</sub>.

Human PBMC cells were purchased from Zhejiang MeisenCTCC. CD4<sup>+</sup> T cells were extracted from PBMC using a negative isolation method with the Human CD4<sup>+</sup> T Cell Isolation Kit (Thermo Fisher, USA) and stimulated with 2.5  $\mu$ g/ml CD3 and 2  $\mu$ g/ml CD28 antibodies (Gibco, USA) for 48 h to induce activation. The constructed Calu6<sup>STK11 KD</sup> and Calu6<sup>STK11 WT</sup> cells in a 1 : 10 ratio were co-cultured with activated CD4<sup>+</sup> T cells in RPMI-1640 medium with 10% FBS and 1% P-S at routine condition.

### qRT-PCR

A cell suspension of A549 (A549<sup>STK11 RES</sup> and A549<sup>STK11 MUT</sup>) and Calu-6 (Calu6<sup>STK11 KD</sup> and Calu6<sup>STK11 WT</sup>) was collected. Total RNA was extracted from cells with TRIzon Reagent (Cwbio, China), and reverse transcription was done with the Hifair II 1<sup>st</sup> Strand cDNA Synthesis Kit (Yeasen, China). Using cDNA as the template, qRT-PCR was completed using UltraSYBR Mixture (Cwbio, China) and the ABI7500 system (Thermo Fisher Scientific, USA). The total cDNA was obtained after multiple high-temperature denaturation (95°C), low-temperature annealing (60°C), and elongation. With  $\beta$ -actin as an internal reference gene, the 2- $\Delta\Delta$ Ct method was used to determine the relative expression level of STK11. Experiments were repeated three times for each group. The primer sequences are shown in Table 1.

### Cell Counting Kit-8 assay

A549 (A549<sup>STK11 RES</sup> and A549<sup>STK11 MUT</sup>) and Calu-6 (Calu6<sup>STK11 KD</sup> and Calu6<sup>STK11 WT</sup>) cell viabilities were measured with cell counting kit-8 (CCK-8; EZB-CK8, China). A 100  $\mu$ l cell suspension ( $5 \times 10^3$  cells) was added to each well of a 96-well plate for culture in a cell culture incubator for 0 h, 24 h, 48 h, 72 h and 96 h. The medium was replaced with serum-free medium, and each well was supplemented with 10  $\mu$ l of CCK-8 solution, followed by 4 h of incu-

bation. Finally, the OD value was assessed at 450 nm by a microplate reader. Each group was tested in triplicate.

### Colony formation assay

The A549 (A549<sup>STK11 RES</sup> and A549<sup>STK11 MUT</sup>) and Calu-6 (Calu6<sup>STK11 KD</sup> and Calu6<sup>STK11 WT</sup>) cell suspension was diluted and seeded into a 6-well plate, with 500 cells per well, and incubated in a 37°C, 5% CO<sub>2</sub> incubator for 14 days. After rinsing twice with PBS, colonies were fixed with 75% ethanol for 15 min, stained with crystal violet, and colonies with more than 50 cells were scored as viable colonies. The images of colonies were captured with a digital camera. The experiment was done three times.

### EDU assay

A549 (A549<sup>STK11 RES</sup> and A549<sup>STK11 MUT</sup>) and Calu-6 (Calu6<sup>STK11 KD</sup> and Calu6<sup>STK11 WT</sup>) cells were seeded (5 × 10<sup>5</sup> cells/well) in a 96-well plate and cultured until adherent. The EDU cell proliferation detection kit (Ribobio, China) was used. EDU solution was diluted to a certain ratio with complete medium, and 100 µl was added to each well of the 96-well plate. After washing with PBS, cells were fixed with 4% paraformaldehyde for 30 min, stained with glycine for 5 min, and then incubated with 0.5% Triton X-100 for 5 min. After staining with Apollo for 30 min, cells were incubated with 0.5% Triton X-100 again for 5 min. Then, 100 µl of 1X Hoechst 33342 reaction solution was added to each well for DNA staining, and cells were observed and photographed under a fluorescence microscope (Leica DM 4000B, Germany).

### Cytotoxicity assay

The cytotoxic effect of CD4<sup>+</sup> T cells on tumor cells was assayed with an lactate dehydrogenase (LDH) cytotoxicity assay kit (Yeasen, China). Effector cells and target cells were plated in a 96-well plate at a ratio of 10 : 1, and different control groups were set up according to the instructions and experimental grouping. After incubation in a cell culture incubator for 4 h, the supernatant of each well was harvested and transferred to a new 96-well plate. Reaction substrate was added and incubated for 30 min, and the optical density value was assessed at 490 nm. Each group was tested in triplicate.

### Transwell assay

Transwell chambers (LABSELECT, China) were placed in a 24-well plate. CD4<sup>+</sup> T cells were plated into the upper chamber (1 × 10<sup>5</sup> cells/ml), and the supernatant from the treated tumor cells or RPMI-1640 was added to lower chamber. Chambers were incubated in a 37°C, 5% CO<sub>2</sub> incubator for 4 h, and migrated cells were collected and counted using a cell counting plate. Each group was tested in triplicate. The migration index was calculated as:

the number of migrated cells in the experimental group/ that in blank group (without chemotactic factors).

### ELISA

We detected the content of the cytokines interferon γ (IFN-γ), interleukin (IL)-2, and tumor necrosis factor α (TNF-α) in the supernatant of tumor cells co-cultured with CD4<sup>+</sup> T cells according to the instructions of the ELISA kit manufacturer. Specifically, the supernatant from the co-culture system was collected using the Human IFN-γ ELISA Kit (ab174443), Human IL-2 ELISA Kit (ab270883), and Human TNF-α ELISA Kit (ab181421) for detecting IFN-γ, IL-2, and TNF-α. All the above test kits were purchased from Abcam (UK).

### Immunohistochemistry (IHC)

The collected patient tumor tissue was dehydrated and embedded in paraffin to prepare sections. After baking, the sections were immersed in xylene I and II for 20 min each to remove paraffin, and then hydrated in 100%, 95%, 85%, and 75% ethanol for 5 min each. Tissue was subjected to antigen retrieval in EDTA solution, followed by sealing of endogenous peroxidase with hydrogen peroxide enzyme-blocking solution. After washing with PBS twice for 5 min each time, the tissue was incubated with normal goat serum homologated with secondary antibody at 37°C for 30 min. Anti-STK11 (Proteintech, China) primary antibody was added, and the tissue was placed overnight in a 4°C refrigerator. The next day, the sections were washed with PBS twice for 5 min each time, incubated with HRP-labeled goat anti-rabbit secondary antibody (Beyotime, China) for 30 min, and stained with DAB. Staining results were observed under an optical microscope, and ten fields (400×) containing positively stained cells were randomly selected for analysis and the average value was recorded for each section.

### Immunofluorescence (IF)

Paraffin sections were dewaxed and hydrated as described in step 2.10, followed by antigen retrieval and blocking with normal goat serum. Sections were then incubated with CD4 (Proteintech, China) primary antibody and placed in a refrigerator at 4°C overnight. Following rinses with PBS, sections were incubated with a fluorescently labeled secondary antibody (Alexa Fluor 488) (Bioss, China) in the dark at 37°C for 30 min. DAPI was added for 5 min of staining in the dark. After rinsing with PBS, sections were sealed with an anti-fluorescence quenching sealing agent and observed under a fluorescence microscope.

### Data analysis

Data were presented as mean values ± standard deviation (mean ± SD). Based on GraphPad Prism 8.0 software, all data were statistically evaluated with at least three bio-

logical replicates for every experiment. For comparisons between two individuals, the non-parametric Mann-Whitney test was employed, and the non-parametric Kruskal-Wallis test was used for comparisons between several individuals.  $P < 0.05$  was regarded as statistically significant.

## Results

### STK11 mutation drives LUAD progression

To further validate expression of STK11 in different LUAD cells, we measured STK11 expression in A549, H460, H2030 cells carrying STK11 mutation and Calu-6 cells without STK11 mutation. Compared with Calu-6 cells, STK11 expression in A549, H460, and H2030 cells was significantly lower ( $p < 0.0001$ ) (Fig. 1A), indicating a significant loss of STK11 expression in LUAD cells with STK11 mutation. We then constructed A549<sup>STK11 RES</sup> and Calu-6<sup>STK11 KD</sup> cell models to investigate the effect of STK11 mutation on LUAD. qRT-PCR revealed that mRNA levels of STK11 were significantly lower in A549<sup>STK11 MUT</sup> cells than in A549<sup>STK11 RES</sup> cells ( $p = 0.0052$ ) (Fig. 1B). qRT-PCR revealed that mRNA levels of STK11 were significantly lower in Calu-6<sup>STK11 KD</sup> cells than in Calu-6<sup>STK11 WT</sup> cells ( $p = 0.0046$ ) (Fig. 1C). CCK-8 assays showed that the loss of the STK11 gene promoted the OD value of A549<sup>STK11 MUT</sup> ( $p = 0.0065$ ) and Calu-6<sup>STK11 KD</sup> ( $p = 0.0104$ ) cells (Fig. 1D, E). Furthermore, the EDU assays indicated that the proliferation ability of A549<sup>STK11 MUT</sup> ( $p = 0.0012$ ) and Calu-6<sup>STK11 KD</sup> ( $p = 0.0099$ ) cells was significantly enhanced (Fig. 1F, G). The colony formation assays also indicated that the proliferation ability of A549<sup>STK11 MUT</sup> ( $p = 0.0042$ ) and Calu-6<sup>STK11 KD</sup> ( $p = 0.0224$ ) cells was significantly enhanced (Fig. 1F, G). These results suggested that STK11 mutation in LUAD cells led to a decrease in STK11 expression and promoted the malignant progression of LUAD.

### STK11 mutation affects the CD4<sup>+</sup> T cell-mediated killing effect on LUAD cells

Studies have shown that LUAD patients with STK11 mutation have less immune cell infiltration, such as B cells, CD8<sup>+</sup> T cells, CD4<sup>+</sup> T cells, macrophages, neutrophils, etc. [46]. To investigate the effect of CD4<sup>+</sup> T cells on LUAD cells with STK11 mutation, we isolated CD4<sup>+</sup> T cells from human PBMC cells, activated them, and co-cultured them with STK11 mutant and wild-type LUAD cell lines (Calu-6<sup>STK11 KD</sup> and Calu-6<sup>STK11 WT</sup>). Cell toxicity and chemotaxis assays assessed killing ability and chemotaxis of CD4<sup>+</sup> T cells against LUAD cells. Compared with Calu-6<sup>STK11 WT</sup> cells, the cytotoxicity of CD4<sup>+</sup> T cells against Calu-6<sup>STK11 KD</sup> cells was significantly lower ( $p = 0.0192$ ), and their chemotaxis ability was also significantly lower ( $p = 0.0085$ ) (Fig. 2A, B). ELISA analysis of the cytokine expression levels in the supernatant of CD4<sup>+</sup> T cells co-cul-

tured with Calu-6 cells revealed a substantial decrease in IFN- $\gamma$  ( $p = 0.0015$ ), IL-2 ( $p = 0.0021$ ), and TNF- $\alpha$  ( $p = 0.015$ ) levels (Fig. 2C-E). Thus, STK11 mutation substantially reduced the killing ability of CD4<sup>+</sup> T cells against LUAD cells.

### STK11 mutation leads to decreased immune cell infiltration in LUAD patients' tumor tissues


To delineate the modulatory role of STK11 mutation in the tumor microenvironment of LUAD, we evaluated the levels of immune cell infiltration in clinical tissue samples from patients with wild-type STK11 and mutant LUAD. By performing IHC analysis to assess STK11 protein expression in different patient tumor tissues, we found that STK11 protein expression in tumor tissues of STK11 mutant patients was substantially lower than that in tumor tissues of wild-type STK11 patients ( $p < 0.0001$ ) (Fig. 3A). IF analysis of CD4<sup>+</sup> T cell infiltration levels in tumor tissues of STK11 wild-type and mutant LUAD patients showed that CD4<sup>+</sup> T cell content was significantly lower in tumor tissues of STK11 mutant patients compared to that of STK11 wild-type patients ( $p < 0.0001$ ) (Fig. 3B). The analysis of clinical tissue samples from LUAD patients revealed that STK11 mutation led to a decrease in immune cell infiltration in tumor tissues, confirming the important modulatory role of STK11 mutation in the tumor microenvironment of LUAD.

## Discussion


Lung adenocarcinoma has a high mortality rate [47]. STK11 mutation is common in LUAD and is associated with poor prognosis [48]. This study explored the potential mechanism of the impact of STK11 mutation on LUAD cells and tissues.

STK11 mutation is associated with lung cancer [49], non-small cell lung cancer [50], hereditary pancreatic cancer [51], breast cancer [52], and LUAD [53]. It is worth noting that LUAD can be caused by various genetic and environmental factors, and *STK11* gene mutations are the commonest [13, 54]. Mutations in STK11 can lead to uncontrolled cell growth and tumor formation [55, 56]. We first investigated the effect of *STK11* gene mutations on tumor progression through gene knockout experiments and found that STK11 mutation promotes the progression of A549 and Calu-6 cells, consistent with a report published in APMIS in 2022 [55]. There are currently no reports on whether STK11 mutation has a beneficial or detrimental effect on the cell activity of CD4<sup>+</sup> T cells. This study, through successive experiments, first demonstrated that STK11 mutation inhibited the cell activity of CD4<sup>+</sup> T cells in a co-culture system with Calu-6 cells.


Immune infiltration refers to the process by which immune cell migrate from the blood to tissues or organs



**Fig. 1.** STK11 mutation promotes the progression of LUAD. **A)** qRT-PCR verification of the expression levels of STK11 in different LUAD cells: A549, H460, H2030 and Calu-6 ( $p < 0.0001$ ). **B)** qRT-PCR detection of transfection efficiency in A549<sup>STK11 RES</sup> and A549<sup>STK11 MUT</sup> cells ( $p = 0.0052$ ). **C)** qRT-PCR detection of transfection efficiency in Calu6<sup>STK11 KD</sup> and Calu6<sup>STK11 WT</sup> cells ( $p = 0.0046$ ). **D)** CCK-8 detection OD value (450 nm) of A549<sup>STK11 RES</sup> and A549<sup>STK11 MUT</sup> cells ( $p = 0.0065$ ). **E)** CCK-8 detection OD value (450 nm) of Calu6<sup>STK11 KD</sup> and Calu6<sup>STK11 WT</sup> cells ( $p = 0.0104$ ).



**Fig. 1.** Cont. **F**) EDU experiment to detect proliferation of A549<sup>STK11 RES</sup> and A549<sup>STK11 MUT</sup> cells (*p* = 0.0012) and Calu6<sup>STK11 KD</sup> and Calu6<sup>STK11 WT</sup> cells (*p* = 0.0099)




**Fig. 1.** Cont. **G**) Colony formation experiment to detect proliferation of A549<sup>STK11 RES</sup> and A549<sup>STK11 MUT</sup> cells ( $p = 0.0042$ ) and Calu6<sup>STK11 KD</sup> and Calu6<sup>STK11 WT</sup> cells ( $p = 0.0224$ ). Data are presented as mean values  $\pm$  standard deviation (mean  $\pm$  SD).  $P < 0.05$  was regarded as statistically significant. Each set of experiments was repeated three times


to resist foreign invaders (such as pathogens or cancer cells). It plays a pivotal role in the immune system's capacity to identify and react to foreign antigens, as well as to maintain tissue homeostasis and prevent the development of autoimmune diseases [57-60]. Previous studies have shown through *in vivo* and *in vitro* experiments that STK11 mutation significantly reduces infiltration levels of NK cells, and inhibits their activity and chemotaxis, and killing of LUAD cells, thereby promoting the progression of LUAD [55]. In addition, a study published in *Frontiers in Oncology* in 2020 showed that *STK11* gene copy number is connected with immune cell infiltration, and the immune cell infiltration levels of LUAD patients with STK11 mutation are much lower than those of the wild type [13]. Subsequently, we investigated the impact of STK11 mutation on immune infiltration levels based on the collected clinical samples and found that STK11 mutation signifi-

cantly reduced the immune infiltration levels of CD4<sup>+</sup> T cells in LUAD tissues, which is consistent with previous research findings.

Based on the above discussion, we concluded that STK11 mutation in LUAD tissues led to reduced infiltration and activation of CD4<sup>+</sup> T cells, thereby promoting tumor growth by producing an immune-suppressive microenvironment. The reduced activity of CD4<sup>+</sup> T cells observed in tumors with STK11 mutation may represent an immune evasion mechanism. This study revealed a mechanism by which STK11 mutation modulated CD4<sup>+</sup> T cells and promoted tumor progression, providing fresh insights into role of STK11 mutation in LUAD and their effects on the immune system. Future research needs to explore likely mechanisms by which STK11 mutation affects immune cell activity and develop effective treatments for STK11 mutation in LUAD.



**Fig. 2.** The effect of LUAD STK11 mutation on the activation and killing effect of CD4<sup>+</sup> T cells. **A)** Cytotoxicity of CD4<sup>+</sup> T cells in co-culture of CD4<sup>+</sup> T cells and tumor cells ( $p = 0.0192$ ). **B)** Chemotaxis of CD4<sup>+</sup> T cells in co-culture of CD4<sup>+</sup> T cells and tumor cells ( $p = 0.0085$ ). **C-E)** ELISA detection of levels of cytokines IFN- $\gamma$  ( $p = 0.0015$ ), IL-2 ( $p = 0.0021$ ) and TNF- $\alpha$  ( $p = 0.015$ ) in co-culture of CD4<sup>+</sup> T cells and tumor cells. Data are presented as mean values  $\pm$  standard deviation (mean  $\pm$ SD).  $P < 0.05$  was regarded as statistically significant. Each set of experiments was repeated three times



**Fig. 3.** Correlation analysis of STK11 and CD4 expression in clinical samples of LUAD. **A)** IHC detection of STK11 expression in tissues of wild-type and mutant LUAD patients (feature image) ( $p < 0.0001$ ). **B)** IF detection of CD4+ T cell infiltration levels in tissues of wild-type and mutant LUAD patients (feature image) ( $p < 0.0001$ ). Data are presented as mean values  $\pm$  standard deviation (mean  $\pm$ SD).  $P < 0.05$  was regarded as statistically significant. Each set of experiments was repeated 15 times

## Funding

This research was supported by Health Science and Technology Project of Zhejiang Province in 2022 (Clinical Research Application Project) (Grant Number: 2022KY1205).

## Disclosures

The study was approved by the Ethics Committee of Wenzhou People's Hospital (KY-2023-165).

The authors declare no conflict of interest.

## References

1. Zhang Q, Zhao Y, Song Z, et al. (2023): Identification of THSD7B and PRMT9 mutations as risk factors for familial lung adenocarcinoma: A case report. *Medicine (Baltimore)* 102: e32872.
2. Li X, Zhang L, Zeng L, et al. (2021): Difficult differential diagnosis of bladder pedicled masses about metastasis from non-small cell lung cancer: A case report. *Cancer Biol Ther* 22: 106-111.
3. Testa U, Pelosi E, Castelli G (2022): Molecular characterization of lung adenocarcinoma combining whole exome sequencing, copy number analysis and gene expression profiling. *Expert Rev Mol Diagn* 22: 77-100.
4. Zarifa A, Albitar A, Kim PY, et al. (2019): Cardiac toxicities of anticancer treatments: chemotherapy, targeted therapy and immunotherapy. *Curr Opin Cardiol* 34: 441-450.
5. Peretz A, Shlomo IB, Nitzan O, et al. (2016): Clostridium difficile infection: Associations with chemotherapy, radiation therapy, and targeting therapy treatments. *Curr Med Chem* 23: 4442-4449.
6. Raj S, Khurana S, Choudhari R, et al. (2021): Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy. *Semin Cancer Biol* 69: 166-177.
7. Ashaie MA, Islam RA, Kamaruzman NI, et al. (2019): Targeting cell adhesion molecules via carbonate apatite-mediated delivery of specific siRNAs to breast cancer cells in vitro and in vivo. *Pharmaceutics* 2019; 11: 309.
8. Das RS, Mukherjee A, Kar S, et al. (2022): Construction of red fluorescent dual targeting mechanically interlocked molecules for live cancer cell specific lysosomal staining and multicolor cellular imaging. *Org Lett* 24: 5907-5912.
9. Chadalapaka G, Jutooru I, Burghardt R, Safe S (2010): Drugs that target specificity proteins downregulate epidermal growth factor receptor in bladder cancer cells. *Mol Cancer Res* 8: 739-750.
10. Brueckl WM, Ficker JH, Zeitler G (2020): Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC). *BMC Cancer* 2020; 20: 1185.
11. Pisapia P, Malapelle U, Troncone G (2019): Liquid biopsy and lung cancer. *Acta Cytol* 2019; 63: 489-496.
12. Farooq H, Bien H, Chang V, et al. (2022): Loss of function STK11 alterations and poor outcomes in non-small-cell lung cancer: Literature and case series of US veterans. *Semin Oncol* 1: S0093-7754(22)00048-3.
13. Li Z, Ding B, Xu J, et al. (2020): Relevance of STK11 mutations regarding immune cell infiltration, drug sensitivity, and cellular processes in lung adenocarcinoma. *Front Oncol* 10: 580027.
14. Hollstein PE, Eichner LJ, Brun SN, et al. (2019): The AMPK-related kinases SIK1 and SIK3 mediate key tumor-suppressive effects of LKB1 in NSCLC. *Cancer Discov* 9: 1606-1627.
15. Delgado TC, Lopitz-Otsoa F, Martinez-Chantar ML (2019): Post-translational modifiers of liver kinase B1/serine/threonine kinase 11 in hepatocellular carcinoma. *J Hepatocell Carcinoma* 6: 85-91.
16. Todsaporn D, Mahalapbutr P, Poo-Arporn RP, et al. (2022): Structural dynamics and kinase inhibitory activity of three generations of tyrosine kinase inhibitors against wild-type, L858R/T790M, and L858R/T790M/C797S forms of EGFR. *Comput Biol Med* 147: 105787.
17. Helfrich BA, Raben D, Varella-Garcia M, et al. (2006): Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. *Clin Cancer Res* 12: 7117-7125.
18. Kim S, Park AK, Cho J (2018): Early emergence of de novo EGFR T790M gatekeeper mutations during erlotinib treatment in PC9 non-small cell lung cancer cells. *Biochem Biophys Res Commun* 503: 710-714.
19. Marini E, Marino M, Gionfriddo G, et al. (2022): Investigation into the use of encorafenib to develop potential PROTACs directed against BRAF(V600E) protein. *Molecules* 27: 8513.
20. Lorentzen HF (2019): Targeted therapy for malignant melanoma. *Curr Opin Pharmacol* 46: 116-121.
21. Voutsadakis IA (2022): The genomic environment of BRAF mutated and BRAF/PIK3CA double mutated colorectal cancers. *J Clin Med* 11: 5132.
22. Sun SY (2013): Impact of genetic alterations on mTOR-targeted cancer therapy. *Chin J Cancer* 32: 270-274.
23. Machino H, Kaneko S, Komatsu M, et al. (2022): The metabolic stress-activated checkpoint LKB1-MARK3 axis acts as a tumor suppressor in high-grade serous ovarian carcinoma. *Commun Biol* 5: 39.
24. Hogg A, Sui Y, Ben-Sasson SZ, et al. (2017): Role of CD4 T cell helper subsets in immune response and deviation of CD8 T cells in mice. *Eur J Immunol* 47: 2059-2069.
25. Kravtsov DS, Erbe AK, Sondel PM, Rakhamilevich AL (2022): Roles of CD4<sup>+</sup> T cells as mediators of antitumor immunity. *Front Immunol* 13: 972021.
26. Parzmaier GP, Gerecke M, Haberkorn O, et al. (2017): ADAP plays a pivotal role in CD4<sup>+</sup> T cell activation but is only marginally involved in CD8<sup>+</sup> T cell activation, differentiation, and immunity to pathogens. *J Leukoc Biol* 101: 407-419.
27. Wang Z, Wang X, Jin R, et al. (2023): LAMP3 expression in the liver is involved in T cell activation and adaptive immune regulation in hepatitis B virus infection. *Front Immunol* 14: 1127572.
28. Bekri S, Rodney-Sandy R, Gruenstein D, et al. (2022): Neo-antigen vaccine-induced CD4 T cells confer protective immunity in a mouse model of multiple myeloma through activation of CD8 T cells against non-vaccine, tumor-associated antigens. *J Immunother Cancer* 10: e003572.
29. Krebs CF, Steinmetz OM (2016): CD4(+) T cell fate in glomerulonephritis: A tale of Th1, Th17, and novel Treg subtypes. *Mediators Inflamm* 2016: 5393894.
30. Teixeira FFC, Cardoso FGR, Ferreira NS, et al. (2022): Effects of calcium hydroxide intracanal medications on T helper

(Th1, Th2, Th9, Th17, and Tfh) and regulatory T (Treg) cell cytokines in apical periodontitis: A CONSORT RCT. *J Endod* 48: 975-984.

31. Barquero-Calvo E, Martirosyan A, Ordonez-Rueda D, et al. (2013): Neutrophils exert a suppressive effect on Th1 responses to intracellular pathogen *Brucella abortus*. *PLoS Pathog* 9: e1003167.
32. Jin X, Bai X, Yang Y, et al. (2020): NLRP3 played a role in *Trichinella spiralis*-triggered Th2 and regulatory T cells response. *Vet Res* 51: 107.
33. Varikuti S, Verma C, Natarajan G, et al. (2021): Micro-RNA155 plays a critical role in the pathogenesis of cutaneous leishmania major infection by promoting a Th2 response and attenuating dendritic cell activity. *Am J Pathol* 191: 809-816.
34. Xu L, Hu G, Xing P, et al. (2021): Corrigendum to “Paclitaxel alleviates the sepsis-induced acute kidney injury via Inc-MALAT1/miR-370-3p/HMGB1 axis” [Life Sci. 2020 Dec 1; 262:118505. doi:10.1016/j.lfs.2020.118505. Epub 2020 Sep 28]. *Life Sci* 272: 119159.
35. Hiltensperger M, Korn T (2018): The interleukin (IL)-23/T helper (Th)17 axis in experimental autoimmune encephalomyelitis and multiple sclerosis. *Cold Spring Harb Perspect Med* 8: a029637.
36. Hyun KH, Gil KC, Kim SG, et al. (2019): Delphinidin chloride and its hydrolytic metabolite gallic acid promote differentiation of regulatory T cells and have an anti-inflammatory effect on the allograft model. *J Food Sci* 84: 920-930.
37. Anderson JL, Khoury G, Fromentin R, et al. (2020): Human immunodeficiency virus (HIV)-infected CCR6+ rectal CD4+ T cells and HIV persistence on antiretroviral therapy. *J Infect Dis* 221: 744-755.
38. Maldini CR, Gayout K, Leibman RS, et al. (2020): HIV-resistant and HIV-specific CAR-modified CD4(+) T cells mitigate HIV disease progression and confer CD4(+) T cell help in vivo. *Mol Ther* 28: 1585-1599.
39. Arneth B (2016): Activated CD4+ and CD8+ T cell proportions in multiple sclerosis patients. *Inflammation* 39: 2040-2044.
40. Krovi SH, Kuchroo VK (2022): Activation pathways that drive CD4(+) T cells to break tolerance in autoimmune diseases. *Immunol Rev* 307: 161-190.
41. Cui C, Wang J, Fagerberg E, et al. (2021): Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses. *Cell* 184: 6101-6118.e13.
42. Li H, Burgueno-Bucio E, Xu S, et al. (2019): CD5 on dendritic cells regulates CD4+ and CD8+ T cell activation and induction of immune responses. *PLoS One* 14: e0222301.
43. Sun JJ, Li HL, Ma H, et al. (2019): SMYD2 promotes cervical cancer growth by stimulating cell proliferation. *Cell Biosci* 9: 75.
44. Yaping W, Zhe W, Zhuling C, et al. (2022): The soldiers needed to be awakened: Tumor-infiltrating immune cells. *Front Genet* 13: 988703.
45. Svensson-Arvelund J, Cuadrado-Castano S, Pantsulaia G, et al. (2022): Expanding cross-presenting dendritic cells enhances oncolytic virotherapy and is critical for long-term anti-tumor immunity. *Nat Commun* 13: 7149.
46. Wang H, Guo J, Shang X, Wang Z (2020): Less immune cell infiltration and worse prognosis after immunotherapy for patients with lung adenocarcinoma who harbored STK11 mutation. *Int Immunopharmacol* 84: 106574.
47. Chen M, Liu X, Du J, et al. (2017): Differentiated regulation of immune-response related genes between LUAD and LUSC subtypes of lung cancers. *Oncotarget* 8: 133-144.
48. Maki-Nevala S, Sarhadi VK, Ronty M, et al. (2016): Hot spot mutations in Finnish non-small cell lung cancers. *Lung Cancer* 99: 102-110.
49. Wohlhieter CA, Richards AL, Uddin F, et al. (2020): Concurrent mutations in STK11 and KEAP1 promote ferroptosis protection and SCD1 dependence in lung cancer. *Cell Rep* 33: 108444.
50. La Fleur L, Falk-Sorqvist E, Smeds P, et al. (2019): Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11. *Lung Cancer* 130: 50-58.
51. Abe K, Kitago M, Kitagawa Y, Hirasawa A (2021): Hereditary pancreatic cancer. *Int J Clin Oncol* 26: 1784-1792.
52. Shiozaki S, Korde LA (2015): Genetics of breast cancer: a topic in evolution. *Ann Oncol* 26: 1291-1299.
53. Ricciuti B, Arbour KC, Lin JJ, et al. (2022): Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status. *J Thorac Oncol* 17: 399-410.
54. Pop-Bica C, Ciocan CA, Braicu C, et al. (2022): Next-generation sequencing in lung cancer patients: A comparative approach in NSCLC and SCLC mutational landscapes. *J Pers Med* 12: 453.
55. Huang Y, Zhang H, Feng J, Tang B (2022): STK11 mutation affects the killing effect of NK cells to promote the progression of lung adenocarcinoma. *APMIS* 130: 647-656.
56. Fan J, Wang K, Zirkin B, Papadopoulos V (2018): CRISPR/Cas9-mediated Tspo gene mutations lead to reduced mitochondrial membrane potential and steroid formation in MA-10 mouse tumor Leydig cells. *Endocrinology* 159: 1130-1146.
57. Miller J (2020): The function of the thymus and its impact on modern medicine. *Science* 369: eaba2429.
58. Huntington ND, Gray DH (2018): Immune homeostasis in health and disease. *Immunol Cell Biol* 96: 451-452.
59. Tan Y, Wang M, Zhang Y, et al. (2021): Tumor-associated macrophages: A potential target for cancer therapy. *Front Oncol* 11: 693517.
60. Lee M, Du H, Winer DA, et al. (2022): Mechanosensing in macrophages and dendritic cells in steady-state and disease. *Front Cell Dev Biol* 10: 1044729.